Oxford Nanopore Technologies
U.K.-based nanopore sequencing company
From Wikipedia, the free encyclopedia
Oxford Nanopore Technologies plc is a UK-based company which develops and sells nanopore-based molecular sensing technology for the real-time analysis of DNA and RNA.[2][3][4] Its platform includes sequencing devices, consumables and software used across research, applied and clinical markets.[5][6][7] It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.[8]
| |
| Type | Public limited company |
|---|---|
| ISIN | GB00BP6S8Z30 |
| Industry | Nanopore sequencing |
| Founded | 2005 |
| Founders |
|
| Headquarters | , |
| Key people |
|
| Revenue |  £223.9 million (2025)[1] |
 £(155.3) million (2025)[1] | |
| £(145.2) million (2025)[1] | |
| Website | nanoporetech |
History
The company was founded in 2005 as a spin-out from the University of Oxford by Hagan Bayley,[9] Gordon Sanghera, and Spike Willcocks, with seed funding from the IP Group.[10] The company made an initial public offering on the London Stock Exchange on 30 September 2021, under the ticker ONT.[11]
In March 2016 the company announced a chemistry upgrade to its nanopore sequencing product 'R9', using a protein nanopore in collaboration with the laboratory of Han Remaut (VIB/Vrije Universiteit Brussel).[12] The company stated in a webcast that R9 is designed to improve error rates and yield.[13]
In December 2025, the company announced that Francis Van Parys would succeed Gordon Sanghera as CEO.[14] Prior to joining Oxford Nanopore, he was President and CEO of Radiometer and held senior leadership roles at Cytiva and GE Healthcare.[14]
Products
The main products of Oxford Nanopore are:
- MinION:[15][16][17] this harmonica-sized portable protein nanopore sequencing USB device has been commercially available since May 2015.[18]
- GridION: this desktop device has been commercially available since March 2017.[19] The device processes up to five MinION flow cells and enables generation of up to 100 Gb of data per run.[20]
- PromethION: a desktop device for sequencing of native DNA or RNA samples.[21] The device contains channels for 144,000 nanopores (in comparison to MinION’s 512)[22] and delivers up to 290 Gb of data per flow cell.[23]
- PromethION 24: this device is a nanopore sequencing platform released in 2019 for DNA and RNA sequencing projects[24]. It 24 flow cells which can be run independently.[25]
- EPI2ME: a procut for customers with limited computational experience to process data without high-performance computing resources and programming expertise.[26][27]
These products are intended to be used for the analysis of DNA, RNA, proteins and small molecules with a range of applications in personalized medicine, Agricultural science and scientific research.[28]